Google Cloud has announced the launch of two new AI-powered life sciences solutions aimed at accelerating drug discovery and precision medicine. These solutions, announced at the Bio-IT World Conference, are set to transform the biotech and pharmaceutical sectors, and public sector organizations.
Target and Lead Identification Suite
The first solution, the Target and Lead Identification Suite, is designed to help researchers better understand the function of amino acids and predict the structure of proteins. This suite will enable biopharma companies to bring therapeutics to market faster by enabling more efficient in silico drug design. Its target identification will help companies quickly predict antibody structures, assess the structure and function of amino acid mutagenesis, and accelerate de novo protein design.
The suite also includes a lead optimization feature that can be used to discover novel, high-quality candidates at low cost for Quantitative Structure Activity Relationship (QSAR) studies or for Free Energy Perturbation (FEP) calculations.
Early adopters of the Target and Lead Identification Suite include multinational pharmaceutical companies like Pfizer, and industry-leading biotech companies like Cerevel.
The second solution, the Multiomics Suite, is designed to accelerate the discovery and interpretation of genomic data, helping companies design precision treatments. This suite advances precision medicine care by transforming multiomics data into insights to advance scientific discoveries. Organizations can use this solution to streamline and accelerate analysis of genomic data, design clinical genomics, accelerate personalized medicine, and interpret genomic data to unlock new discoveries.
The Multiomics Suite is cloud agnostic, allowing organizations to leverage existing investments in multiomics in a simplified environment. It also offers complete traceability through Vertex AI, so customers can organize millions of artifacts in their cloud environments.
Colossal Biosciences, one of the early adopters of the Multiomics Suite, reported a 52% reduction in overall cost and an 88% reduction in time to execute whole genome sequence analysis when compared with open-source tools.
A New Era of Drug Discovery and Precision Medicine
These new solutions from Google Cloud are set to revolutionize the field of drug discovery and precision medicine. By leveraging the power of AI, these tools can accelerate the drug discovery process, bringing therapeutics to market faster and potentially having a positive impact on the lives of patients waiting for life-saving treatments.
With privacy and security at the forefront of all its products and solutions, Google Cloud ensures the protection of patient data through its reliable infrastructure and secure data storage that support HIPAA compliance.
These advancements by Google Cloud are a testament to the potential of AI in transforming the healthcare industry. As these tools become more widely adopted, we can expect to see significant improvements in the speed and efficiency of drug discovery and the development of precision medicine.